首页 / 资料库 / 文献详情

[Population pharmacokinetic/pharmacodynamic modeling of warfarin by nonlinear mixed effects model].

Rongfang LinWei-Wei LinChanglian WangPinfang HuangSu-jun Fang

2015PubMedPharmacology, Toxicology and Pharmaceutics被引 5

出版方页面 →

摘要

The study aimed to establish a population pharmacokinetic/pharmacodynamic (PPK/PD) model of warfarin. PCR-RFLP technique was used to genotype the CYP2C9 and VKORC1 polymorphisms of 73 patients. RP-HPLC-UV method was used to determine the 190 plasma concentrations of warfarin. Application of NONMEM, the clinical information and 263 international normalized ratio (INR) monitoring data were used to investigate the effect of genetic, physiological, pathological factors, other medication on clearance and anticoagulant response. The final model of warfarin PPK/PD was described as follows: CL = θCL · (WT/60)θWT · θCYP · eηCL (if CYP2C9*1/*1, θCYP = 1; if *1/*3, θCYP = 0.708); EC50 = θEC50 · θVKOR · eηEC50 (if VKORC1- 1639AA, θVKOR = 1; if GA, θVKOR = 2.01; V = θV; K(E0) = θK(E0); Emax = θEmax; E0 = θE0 · eηE0. Among them, the body weight (WT), CYP2C9 and VKORC1 genotype had conspicuous effect on warfarin PK/PD parameters. The goodness diagnosis, Bootstrap, NPDE verification showed that the final model was stable, effective and predictable. It may provide a reference for opitimizing the dose regimen of warfarin.

引用本文(GB/T 7714)

Rongfang Lin, Wei-Wei Lin, Changlian Wang, 等. [Population pharmacokinetic/pharmacodynamic modeling of warfarin by nonlinear mixed effects model].[J]. PubMed, 2015.

引文网络

参考文献与被引分析加载中…

本站仅收录题录与摘要供学习参考,全文版权归属出版方;如有侵权请联系我们删除。